Business
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis – – Expect to report topline data from both Phase 2 Seabreeze STAT studies mid-2026 – – $20.2 million private placement financing closed on March 31, 2026 – SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical compa
About this update from Connect Biopharma Holdings Limited
[{"type":"image","alt":"Connect Biopharma Holdings Limited","displaySize":"","headline":null,"caption":"Connect Biopharma Holdings Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/f3a290cabae4a8e314429e2a9e477131"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dz_ZjOzH0NEJ9AV78Fe_nA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNg--/https://media.zenfs.com/en/globenewswire.com/f3a290cabae4a8e314429e2a9e477131","width":300,"height":83},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/dz_ZjOzH0NEJ9AV78Fe_nA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNg--/https://media.zenfs.com/en/globenewswire.com/f3a290cabae4a8e314429e2a9e477131","width":300,"height":83}},"lazy":false},{"type":"text","content":"– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –","length":165,"tagName":"p"},{"type":"text","content":"– Expect to report topline data from both Phase 2 Seabreeze STAT studies mid-2026 –","length":83,"tagName":"p"},{"type":"text","content":"– $20.2 million private placement financing closed on March 31, 2026 –","length":70,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three months ended March 31, 2026, and provided a business update.","length":362,"tagName":"p"},{"type":"text","content":"“We have had a strong start to the year as we continue to build upon the body of preclinical and clinical evidence supporting the potential of rademikibart to treat acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD), each a significant commercial opportunity where no biologics are currently approved or being developed,” said Barry Quart, Chief Executive Officer of Connect Biopharma. “The recent data from our Phase 1 intravenous (IV) clinical pharmacology study for rademikibart are encouraging, demonstrating faster onset, lower dosing, and the potential for differentiated pricing in the hospital setting if approved. In addition, the recent independent data mo...